Advicenne - Asset Resilience Ratio
Advicenne (ALDVI) has an Asset Resilience Ratio of 7.65% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Advicenne working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Advicenne's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ALDVI asset base.
Liquid Assets Composition Over Time
This chart breaks down Advicenne's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ALDVI current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €515.00K | 7.65% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €515.00K | 7.65% |
Asset Resilience Insights
- Limited Liquidity: Advicenne maintains only 7.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Advicenne Industry Peers by Asset Resilience Ratio
Compare Advicenne's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Advicenne (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Advicenne.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 34.17% | €3.25 Million ≈ $3.80 Million |
€9.51 Million ≈ $11.11 Million |
-0.09pp |
| 2023-12-31 | 34.26% | €4.25 Million ≈ $4.97 Million |
€12.41 Million ≈ $14.51 Million |
-24.12pp |
| 2022-12-31 | 58.38% | €8.32 Million ≈ $9.73 Million |
€14.26 Million ≈ $16.67 Million |
-8.81pp |
| 2021-12-31 | 67.18% | €12.69 Million ≈ $14.83 Million |
€18.88 Million ≈ $22.07 Million |
-2.68pp |
| 2020-12-31 | 69.87% | €16.77 Million ≈ $19.61 Million |
€24.00 Million ≈ $28.06 Million |
-12.39pp |
| 2019-12-31 | 82.26% | €18.85 Million ≈ $22.04 Million |
€22.92 Million ≈ $26.80 Million |
+1.96pp |
| 2018-12-31 | 80.30% | €26.64 Million ≈ $31.14 Million |
€33.17 Million ≈ $38.78 Million |
-14.18pp |
| 2017-12-31 | 94.47% | €36.48 Million ≈ $42.65 Million |
€38.62 Million ≈ $45.15 Million |
+45.86pp |
| 2016-12-31 | 48.62% | €1.58 Million ≈ $1.85 Million |
€3.26 Million ≈ $3.81 Million |
-3.13pp |
| 2015-12-31 | 51.75% | €1.54 Million ≈ $1.80 Million |
€2.98 Million ≈ $3.48 Million |
+7.10pp |
| 2014-12-31 | 44.65% | €1.44 Million ≈ $1.68 Million |
€3.22 Million ≈ $3.77 Million |
-- |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more